Quick Answer
Scinai Immunotherapeutics Ltd. reported Cash and Equivalents of $1.96 million for fiscal year 2024.
Scinai Immunotherapeutics Ltd. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2024 | $1.96M | -59.7% |
| 2023 | $4.87M | -65.4% |
| 2022 | $14.07M | -19.0% |
| 2021 | $17.37M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| March 31, 2023 | $10.80M | -29.8% | -23.3% |
| December 31, 2022 | $14.07M | — | -8.6% |
| March 31, 2022 | $15.39M | — | — |
- Scinai Immunotherapeutics Ltd. showed a decrease of -59.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2021–2024 period, Scinai Immunotherapeutics Ltd.’s cash and equivalents has declined by 88.7% (from $17.37 million to $1.96 million).
- The most recent figure is from Scinai Immunotherapeutics Ltd.’s fiscal year 2024 report (Form 20-F), filed with the SEC on May 7, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: